OAM
MRSN

Oxford Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Oxford Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,615
Closed -$93.5K – 630
2024
Q4 		$93.5K Buy
+2,615
New +$135K 0.04% 400
2024
Q2 		– Sell
-663
Closed -$74.3K – 374
2024
Q1 		$74.3K Buy
+663
New +$65.9K 0.08% 237
2020
Q1 		– Sell
-8,065
Closed -$1.16M – 869
2019
Q4 		$1.16M Buy
8,065
+981
+14% +$71.7K 0.03% 772
2019
Q3 		$280K Buy
7,084
+1,441
+26% +$105K 0.01% 1484
2019
Q2 		$571K Buy
+5,643
New +$665K 0.01% 1221

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Oxford Asset Management's MRSN Position: Q1 2025 in Review

Oxford Asset Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 2,615 shares — an estimated $93.5K sold.

Oxford Asset Management first reported a position in MRSN in Q2 2019 and held it in 5 quarters. The position peaked at $1.16M in Q4 2019. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Oxford Asset Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oxford Asset Management sold 2,615 Mersana Therapeutics shares in Q1 2025, an estimated $93.5K.
  • Oxford Asset Management first reported a position in Mersana Therapeutics in Q2 2019 and held it in 5 quarters.
  • Oxford Asset Management's Mersana Therapeutics position peaked at $1.16M in Q4 2019.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Oxford Asset Management's 13F filing for Q1 2025, filed 15 May 2025.